Skip to main content

Advertisement

SpringerLink
Log in

Utility of fosfomycin as antibacterial prophylaxis in patients with hematologic malignancies

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

Prolonged and profound neutropenia is common among hematology and hematopoietic stem cell transplant (HSCT) patients as a result of chemotherapy. The National Comprehensive Cancer Network (NCCN) and Infectious Diseases Society of America (IDSA) currently recommend antibacterial prophylaxis in patients who are deemed at intermediate or high risk for infection. Specifically, fluoroquinolone prophylaxis should be considered for high-risk neutropenic patients. However, with prolonged and frequent exposure to fluoroquinolones, these high-risk patients may develop resistance to these agents. Patients may also have allergies or other contraindications which prohibit the use of fluoroquinolones for antibacterial prophylaxis. Unfortunately, there is no standard recommendation for alternative antimicrobial therapy in this patient population, as well as there is a lack of data to support the use of potential alternative agents.

Methods

Currently, Yale-New Haven Hospital utilizes fosfomycin for antibacterial prophylaxis in patients who are not eligible for fluoroquinolone therapy. The primary objective of this study was to assess the incidence of breakthrough infections in this population receiving fosfomycin. Secondary objectives included organisms identified, types of breakthrough infections, resistance patterns, and time from initiation to onset of fever.

Results

Of the 42 patients who received fosfomycin, 25 patients with 42 admissions met inclusion criteria. A total of 8 (19%) breakthrough infections occurred during the 42 admissions. Organisms included Klebsiella spp. (5), Streptococcus mitis/viridans (2), Pseudomonas aeruginosa (1), and coagulase-negative staphylococcus (1). Infections included the following: bacteremia (7), cellulitis (1), and urine (1).

Conclusion

Given the low rate of breakthrough infections, fosfomycin may be a potential alternative option for antibacterial prophylaxis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Baden LR, Swaminathan S, Angarone M, Blouin G, Camins BC, Casper C, Cooper B, Dubberke ER, Engemann AM, Freifeld AG, Greene JN, Ito JI, Kaul DR, Lustberg ME, Montoya JG, Rolston K, Satyanarayana G, Segal B, Seo SK, Shoham S, Taplitz R, Topal J, Wilson JW, Hoffmann KG, Smith C (2016) Prevention and treatment of cancer-related infections, version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw 14(7):882–813. https://doi.org/10.6004/jnccn.2016.0093

    Article  CAS  Google Scholar 

  2. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 52(4):e56–e93. https://doi.org/10.1093/cid/cir073

    Article  PubMed  Google Scholar 

  3. Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, Stuart N, Rea D, Bower M, Fernando I, Huddart R, Gollins S, Stanley A, Simple Investigation in Neutropenic Individuals of the Frequency of Infection after Chemotherapy +/- Antibiotic in a Number of Tumours (SIGNIFICANT) Trial Group (2005) Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 353(10):988–998. https://doi.org/10.1056/NEJMoa050078

    Article  CAS  PubMed  Google Scholar 

  4. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D’Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Foà R, Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) Infection Program (2005) Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353(10):977–987. https://doi.org/10.1056/NEJMoa044097

    Article  CAS  PubMed  Google Scholar 

  5. Segal BH, Freifeld AG (2007) Antibacterial prophylaxis in patients with neutropenia. J Natl Compr Cancer Netw 5(2):235–232. https://doi.org/10.6004/jnccn.2007.0023

    Article  CAS  Google Scholar 

  6. Kern WV, Steib-Bauert M, de With K, Reuter S, Bertz H, Frank U, von Baum H (2005) Fluoroquinolone consumption and resistance in haematology-oncology patients: ecological analysis in two university hospitals, 1999-2002. J Antimicrob Chemother 55(1):57–60. https://doi.org/10.1093/jac/dkh510

    Article  CAS  PubMed  Google Scholar 

  7. Rangaraj G, Granwehr BP, Jiang Y, Hachem R, Raad I (2010) Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms. Cancer 116(4):967–963. https://doi.org/10.1002/cncr.24812

    Article  PubMed  Google Scholar 

  8. Therriault BL, Wilson JW, Barreto JN, Estes LL (2010) Characterization of bacterial infections in allogeneic hematopoietic stem cell transplant recipients who received prophylactic levofloxacin with either penicillin or doxycycline. Mayo Clin Proc 85(8):711–718. https://doi.org/10.4065/mcp.2010.0006

    Article  PubMed  PubMed Central  Google Scholar 

  9. Pepin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, Leblanc M, Rivard G, Bettez M, Primeau V, Nguyen M, Jacob CE, Lanthier L (2005) Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile associated diarrhea: a cohort study during an epidemic in Quebec. CID 41(9):1254–1260. https://doi.org/10.1086/496986

    Article  CAS  Google Scholar 

  10. Kamboj M, Chung D, Seo SK et al (2011) The changing epidemiology of vancomycin-resistant enterococcus (VRE) bacteremia in allogeneic haematopoietic stem cell transplant (HSCT) recipients. Biol Blood Marrow Transplant 16:1579–1571

    Google Scholar 

  11. Reffert JL, Smith WJ (2014) Fosfomycin for the treatment of resistant Gram negative bacterial infections. Pharmacotherapy 34(8):845–857. https://doi.org/10.1002/phar.1434

    Article  CAS  PubMed  Google Scholar 

  12. Sastry S, Doi Y (2016) Fosfomycin: resurgence of an old companion. J Infect Chemother 22(5):273–280. https://doi.org/10.1016/j.jiac.2016.01.010

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Bergan T (1990) Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity. Infection 2:S65–S69

    Article  Google Scholar 

  14. Bergan T, Thorsteinsson SB, Albini E et al (1993) Pharmacokinetic profile of fosfomycin trometamol. Chemotherapy 39(5):297–291. https://doi.org/10.1159/000239140

    Article  CAS  PubMed  Google Scholar 

  15. Wojenski DJ, Barreto JN, Wolf RC, Tosh PK (2014) Cefpodoxime for antimicrobial prophylaxis in neutropenia: a retrospective case series. Clin Ther 36(6):976–981. https://doi.org/10.1016/j.clinthera.2014.04.013

    Article  CAS  PubMed  Google Scholar 

  16. Kyle JM, Stollings JL, White KD, Noto MJ, Wheeler AP (2015) Fosfomycin for multidrug treatment of Klebsiella pneumoniae carbapenemase bacteremia. Ann Pharmacother 49(3):366–367. https://doi.org/10.1177/1060028014564395

    Article  PubMed  Google Scholar 

  17. Los-Arcos I, Pigrau C, Rodriguez-Pardo D et al (2015) Long term fosfomycin-tromethamine oral therapy for difficult to treat chronic bacterial prostatitis. Antimicrob Agents Chemother 60(3):1854–1858. https://doi.org/10.1128/AAC.02611-15

    Article  CAS  PubMed  Google Scholar 

  18. Grayson ML, Macesic N, Trevillyan J, Ellis AG, Zeglinski PT, Hewitt NH, Gardiner BJ, Frauman AG (2015) Fosfomycin for treatment of prostatitis: new tricks for old dogs. CID 61(7):1141–1143. https://doi.org/10.1093/cid/civ436

    Article  CAS  Google Scholar 

  19. Aguilar-Company J, Los-Arcos I, Pigrau C, Rodríguez-Pardo D, Larrosa MN, Rodríguez-Garrido V, Sihuay-Diburga D, Almirante B (2016) Potential use of fosfomycin-tromethamine for treatment of recurrent Campylobacter species enteritis. Antimicrob Agents Chemother 60(7):4398–4400. https://doi.org/10.1128/AAC.00447-16

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, Yale-New Haven Hospital, 20 York Street, New Haven, CT, 06510, USA

    Tanya Zapolskaya, Sarah Perreault & Dayna McManus

  2. Department of Internal Medicine, Infectious Disease Section, Yale-New Haven Hospital, 20 York Street, New Haven, CT, 06510, USA

    Jeffrey E. Topal

Authors
  1. Tanya Zapolskaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sarah Perreault
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dayna McManus
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jeffrey E. Topal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarah Perreault.

Ethics declarations

Conflict of interest

I have no financial relationship with the organization that sponsored the research. I have full control of all primary data and agree to allow the journal to review the data if requested.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zapolskaya, T., Perreault, S., McManus, D. et al. Utility of fosfomycin as antibacterial prophylaxis in patients with hematologic malignancies. Support Care Cancer 26, 1979–1983 (2018). https://doi.org/10.1007/s00520-017-4040-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-017-4040-x

Keywords

Search

Navigation